4D Molecular Therapeutics, Inc. 4

CEO David Kirn sold 12,415 shares of 4D Molecular Therapeutics, Inc. common stock at about $10.05 per share under a 10b5-1 plan.

On August 3, 2026, David Kirn, President and Chief Executive Officer of 4D Molecular Therapeutics, Inc., sold 12,415 shares of the company’s common stock at a weighted average price of $10.0461 per share under a Rule 10b5-1 trading plan adopted on January 9, 2026, for total proceeds of approximately $124,700. Following this planned disposition, Kirn’s direct ownership stood at 871,737 shares of common stock, which, using the transaction price as a proxy, represents an equity stake valued at roughly $8.76 million. The sale was executed in multiple trades within a price range of $10.00 to $10.1250 per share, and the reporting person has undertaken to provide detailed breakdowns of individual trade prices and quantities upon request, as noted in the Form 4 footnotes.

Filing Facts

CIK

1650648

Ticker

FDMT

Form

4

Source Type

fda

Accession

0001193125-26-333014

Alert Tier

5